• About
  • Contact
  • Support Funtrafoo
  • Work With Us
No Result
View All Result
  • Home
  • FOOD
  • TRAVEL
  • HEALTH
  • TECHNOLOGY
  • LIFESTYLE
  • ENTERTAINMENT
  • EVENTS
  • FEEDS
  • WEB STORIES
  • Home
  • FOOD
  • TRAVEL
  • HEALTH
  • TECHNOLOGY
  • LIFESTYLE
  • ENTERTAINMENT
  • EVENTS
  • FEEDS
  • WEB STORIES
No Result
View All Result
No Result
View All Result
Home Daily Feeds

Pierre Fabre and Lonza Enter Manufacturing Agreement for W0180 Antibody Drug Product

by PR Newswire
June 15, 2022
Reading Time: 5 mins read
0 0
0
ADVERTISEMENT
Share on FacebookShare on Twitter

Also Read

ZS Cares build city’s first ever STEM Robotics AI lab for Pune Zilla Parishad school students

Lonza will provide cGMP drug product (DP) manufacturing services for clinical supply from its fill and finish facility at Stein, Switzerland. Lonza’s ability to provide exemplary drug product development and manufacturing services offers customers innovative solutions and the possibility to supply high-quality products for clinical use.

Jean-Luc Lowinski, Pierre Fabre Medical Care CEO, said: “We are delighted to entrust the production of the W0180 Drug Product to Lonza. Its Drug Product Services are well-suited for our innovative therapy manufacturing needs. The W0180 will be manufactured in Lonza’s GS Xceed® Expression CHO System, also successfully used for the IGF1R and cMet antibodies discovered by Pierre Fabre.”

About W0180

W0180 is a first-in-class antibody targeting VISTA (V-domain Ig suppressor of T cell Activation). VISTA is a negative checkpoint regulator of T cell response. VISTA is expressed within the tumor microenvironment, where its inhibition can enhance antitumor immune responses. Furthermore, an increase in VISTA expression has been reported after treatment with anti-PD1/L1 and anti-CTLA4. This confirms that VISTA may play a key role as a mechanism of resistance to the currently used immunotherapies. W0180 given to patients as a single agent or in combination with anti-PD1/L1 therapy has a potential in multiple cancer indications, including those with myeloid immunosuppressive infiltrates where the VISTA pathway is expressed.

About Pierre Fabre

The Pierre Fabre Group is the second largest private French healthcare group and the second largest dermo-cosmetics manufacturer in the world. In 2021, it generated €2.5 billion in revenues, 66% of which came from international sales. Pierre Fabre employs some 9500 people worldwide and manufactures over 95% of its products in France. Its portfolio includes several medical franchises and international brands, including Pierre Fabre Oncology, Pierre Fabre Dermatology, Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma and Pierre Fabre Oral Care.

In oncology, Pierre Fabre enjoys over 35 years of experience in discovery, development, manufacturing and marketing, with a portfolio of therapies covering colorectal, breast, lung cancers, melanoma and pre-cancerous conditions, such as actinic keratosis. Pierre Fabre’s innovation and commercialization efforts in oncology are focused on targeted therapies, biotherapies and immuno-oncology.

The Pierre Fabre Group is 86%-owned by the Pierre Fabre Foundation, a public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan.

Further information about Pierre Fabre can be found at www.pierre-fabre.com, @PierreFabre.

Pierre Fabre Contact Details

Laure Sgandurra

Oncology Communication Manager

laure.sgandurra@pierre-fabre.com

Logo – https://mma.prnewswire.com/media/1836798/Pierre_Fabre_Lonza_Logo.jpg

(This story is auto-generated from PR Newswire)

Tags: PR NewswirePress Releases
ShareTweetSendShare

Related Posts

ZS Cares build city’s first ever STEM Robotics AI lab for Pune Zilla Parishad school students

ZS Cares build city’s first ever STEM Robotics AI lab for Pune Zilla Parishad school students

July 6, 2022
1
Tredence Inc. Recognized as 2022 Microsoft Analytics Partner of the Year

Tredence Inc. Recognized as 2022 Microsoft Analytics Partner of the Year

July 6, 2022
0
NSDC, Auxilo Finserve collaborate to support funding for skilling & vocational courses; Aim to create portfolio of INR 1,000 crore over next 3 years

NSDC, Auxilo Finserve collaborate to support funding for skilling & vocational courses; Aim to create portfolio of INR 1,000 crore over next 3 years

July 6, 2022
0
TCG Lifesciences inaugurates a new R&D facility in Pune, as part of a major expansion

TCG Lifesciences inaugurates a new R&D facility in Pune, as part of a major expansion

July 5, 2022
1
No Result
View All Result
  • Coronavirus Vaccine Prices In India and Other Countries

    Coronavirus Vaccine Prices In India and Other Countries. Is Covid Vaccine Free?

    21 shares
    Share 21 Tweet 0
  • Padma Vibhushan, Padma Bhushan, Padma Shri: Full List Of Padma Award Winners 2021

    15 shares
    Share 15 Tweet 0
  • Importance And Benefits Of Vitamin D Rich Food

    1 shares
    Share 1 Tweet 0
  • Yoga Beginner’s Guide – Tips Before Attending The First Yoga Class

    1 shares
    Share 1 Tweet 0
  • Parliament of India: नया देश नया भवन

    0 shares
    Share 0 Tweet 0

Recent Posts

  • Steps To Download Covid-19 Vaccine Certificate Using Whatsapp
  • Celebrate International Cat Day (World Cat Day) On 8 August
  • Meet Neeraj Chopra Who Won 1st Gold Medal For India In Tokyo Olympics 2021
  • Robin Hood Army New Initiative #Mission28States To Help Vaccinate Underprivileged, Serve 5 Mn Meals
  • Top 10 most livable cities in the world
  • Home
  • Contact Us
  • About Us
  • Support Funtrafoo
  • Authors
FUN * TRAVEL * FOOD

© 2021 www.funtrafoo.com.

No Result
View All Result
  • Home
  • FOOD
  • TRAVEL
  • HEALTH
  • TECHNOLOGY
  • LIFESTYLE
  • ENTERTAINMENT
  • EVENTS
  • FEEDS
  • WEB STORIES

© 2021 www.funtrafoo.com.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In